• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Roche finalizes acquisition of Kapa Biosystems

Roche finalizes acquisition of Kapa Biosystems

December 8, 2015
CenterWatch Staff

Pleasanton, Calif.-based Roche today announced regulatory clearance to finalize acquisition of Kapa Biosystems, a privately held company based in Wilmington, Mass.

Kapa Biosystems is a provider of genomic tools in the life sciences sector that employs proprietary technologies to optimize enzymes for next-generation sequencing (NGS), as well as polymerase chain reaction (PCR) and real-time PCR applications.

“The completion of this acquisition represents significant advancement in Roche’s commitment to develop a differentiated NGS portfolio that will provide our customers with a complete genetic testing solution,” said Dan Zabrowski, head of Roche Tissue Diagnostics and Sequencing Solutions. “Combining Kapa’s proprietary protein engineering technology and impressive portfolio of NGS reagents with Roche’s offerings and expertise adds to an already robust portfolio of NGS target enrichment products. We look forward to building on our NGS offerings with this unique technology and the combined experience of Kapa and Roche employees.”

Kapa co-founder and CTO Trey Foskett noted, “We are excited to officially become part of the Roche family and look forward to further contributing, on a global scale, to the future of genomics and sequencing. This partnership will accelerate our ability to pioneer new technologies and expand our product portfolio, with the ultimate goal of improving healthcare through more personalized medicine.”

Financial terms of the transaction were not disclosed.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing